SkyQuest Technology Group recently introduced Liquid Biopsy Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Liquid Biopsy Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Liquid Biopsy Market size was valued at US$ 10.32 Billion in 2023 and is poised to grow from US$ 11.48 Billion in 2024 to US$ 26.85 Billion by 2032, growing at a CAGR of 11.21% during the forecast period (2025-2032).
Growth factors for the liquid biopsy market growth include a growing prevalence of cancer, technological advancements in the field of cancer diagnostics, and a growing preference for minimally invasive cancer diagnostics. Moreover, ongoing research in liquid biopsy assays and tests, aided by the rising adoption and development of multi-cancer early detection tests, presents growth opportunities for the overall market.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/liquid-biopsy-market
The 2025 global Liquid Biopsy Market report provides a comprehensive analysis of key industry players, market trends, pricing structures, and competitive dynamics, offering insights into the market landscape from 2025 to 2032. As a rapidly evolving sector, the Liquid Biopsy Market drives economic growth, innovation, and technological advancements through the development, production, and distribution of products and services. This report highlights the market’s growth potential and its impact on global industries, providing valuable insights for stakeholders, investors, and policymakers.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Liquid Biopsy Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
The liquid biopsy market is segmented by Product & Services, Circulating Biomarker, Clinical Application, Technology, Application, Sample Type, End-User and Region. Based on Product & Services, the market is segmented into Assay Kits, Instruments, and services. Based on Circulating Biomarker, the market is segmented into Circulating Tumor Cells, Circulating Nucleic Acids Exosome/Microvesicle, Circulating Tumor DNA, Cell-free DNA, Extracellular Vesicles, and Others. Bases on Clinical Applications, the market is segmented into Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring.
Based on Technology, the market is segmented into Multi-Gene Parallel Analysis using NGS, and Single-Gene Analysis using PCR. Based on Application, the market is segmented into Cancer Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others), Non-Cancer Application (Non-Invasive Prenatal Testing, Organ Transplantation, and Infectious Disease Testing), Reproductive Health. Based on Sample Type, the market is segmented into Blood Samples, Urine Sample, Saliva Sample, and Others. Based on End-User the market is segmented into Hospitals & Clinics, Diagnostic Centers, Reference Laboratories, Academic & Research Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
Liquid Biopsy Market – Regional Analysis:
– Liquid Biopsy North America Market includes (Canada, Mexico, USA)
– Liquid Biopsy Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Liquid Biopsy Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Liquid Biopsy South America Market includes (Brazil, Argentina)
– Liquid Biopsy Oceania Market (Australia & New Zealand)
Top Market Players in Liquid Biopsy Market are:
F. Hoffmann-La Roche Ltd (Switzerland)
Thermo Fisher Scientific Inc. (US)
Illumina, Inc. (US)
Guardant Health, Inc. (US)
Biocept, Inc. (US)
Sysmex Corporation (Japan)
Menarini Silicon Biosystems (Italy)
Natera, Inc. (US)
Biocartis Group NV (Belgium)
Personal Genome Diagnostics Inc. (US)
Bio-Rad Laboratories, Inc. (US)
OncoCyte Corporation (US)
Adaptive Biotechnologies Corporation (US)
Angle PLC (United Kingdom)
Epic Sciences, Inc. (US)
Neogenomics Laboratories (US)
CellMax Life (US)
Menarini-Silicon Biosystems (Italy)
Lunglife AI Inc. (US)
Vortex Biosciences (US)
Take Action Now: Secure Your Liquid Biopsy Market Today – https://www.skyquestt.com/buy-now/liquid-biopsy-market
FAQ
– What challenges and constraints are affecting the market?
– What geographical variables are influencing the Liquid Biopsy market?
– How does the Value Chain concept offer insights into market dynamics?
– Which country dominates the market?
– Which is the leading formulation type for Liquid Biopsy Market?
Forward-Looking Insights
The Liquid Biopsy Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
